Baxiva

Startup

Over 50% of women will have a urinary tract infection (UTI) at least once in their lives, with 25% of women suffering from recuring infections. The majority of UTIs are caused by the bacterium Escherichia coli, and the only current treatment is to prescribe antibiotics. E. coli has a growing rate of resistance to antibiotics, meaning that our current solutions to treat UTIs are becoming less effective, and the cost of treatment is rising. To address this problem, we at baxiva have developed a vaccine that will prevent UTIs caused by E. coli. Our vaccine targets the unique surface capsule antigens of E. coli, allowing us to prevent infection on a strain-specific level. Our vaccine will provide a broad and robust protection from local and systemic infection, preventing sepsis and significantly reducing the burden that UTIs have on the healthcare system and women everywhere.